These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8021742)

  • 21. Monoclonal antibody-based therapies for hematologic malignancies.
    Multani PS; Grossbard ML
    J Clin Oncol; 1998 Nov; 16(11):3691-710. PubMed ID: 9817291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.
    Di Fede G; Bronte G; Rizzo S; Rolfo Cervetto C; Cocorullo G; Gulotta G; Bazan V; Russo A
    Expert Opin Biol Ther; 2011 Nov; 11(11):1433-45. PubMed ID: 21663530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human monoclonal antibodies: prospects for the therapy of cancer.
    Wong JH; Irie RF; Morton DL
    Semin Surg Oncol; 1989; 5(6):448-52. PubMed ID: 2556770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse effects of the humanized antibodies used as cancer therapeutics.
    Klastersky J
    Curr Opin Oncol; 2006 Jul; 18(4):316-20. PubMed ID: 16721123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anti-idiotype vaccines for immunotherapy.
    Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
    Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment.
    Rombouts MD; Swart EL; VAN DEN Eertwegh AJM; Crul M
    Anticancer Res; 2020 Mar; 40(3):1201-1218. PubMed ID: 32132017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies.
    DeNardo SJ; DeNardo GL; O'Grady LF; Hu E; Sytsma VM; Mills SL; Levy NB; Macey DJ; Miller CH; Epstein AL
    Int J Cancer Suppl; 1988; 3():96-101. PubMed ID: 3209308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies in cancer immunotherapy.
    Reisfeld RA
    Clin Lab Med; 1992 Jun; 12(2):201-16. PubMed ID: 1611818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Brief overview on the studies of monoclonal antibody].
    Tsukagoshi S
    Nihon Rinsho; 2002 Mar; 60(3):435-8. PubMed ID: 11904954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
    Pimm MV
    Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.
    Vinay DS; Kwon BS
    Expert Opin Ther Targets; 2016; 20(3):361-73. PubMed ID: 26428392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies as therapeutics in human malignancies.
    Pandey M; Mahadevan D
    Future Oncol; 2014 Mar; 10(4):609-36. PubMed ID: 24754592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
    Murray JL; Cunningham JE; Brewer H; Mujoo K; Zukiwski AA; Podoloff DA; Kasi LP; Bhadkamkar V; Fritsche HA; Benjamin RS
    J Clin Oncol; 1994 Jan; 12(1):184-93. PubMed ID: 8270976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab: a B-cell depletion therapy for dermatologic disease.
    Prajapati V; Mydlarski PR
    Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies and hematologic malignancies.
    Smith MR
    Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of monoclonal antibodies to tumor diagnosis and therapy.
    Rosen ST; Winter JN; Epstein AL
    Ann Clin Lab Sci; 1983; 13(3):173-84. PubMed ID: 6347022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.